ライフサイエンスコーパス: Crohn's disease

1 119; 59 with ulcerative colitis and 60 with Crohn's disease).

2 RC (222 with ulcerative colitis and 100 with Crohn's disease).

3 ecrease the risk of relapse in patients with Crohn's disease.

4 iation study in two cohorts of patients with Crohn's disease.

5 colitis is an experimental model that mimics Crohn's disease.

6 lth-care costs in paediatric and adult onset Crohn's disease.

7 ry diseases such as rheumatoid arthritis and Crohn's disease.

8 patients with moderately-to-severely active Crohn's disease.

9 19 might be a viable therapeutic approach in Crohn's disease.

10 pulations with moderately to severely active Crohn's disease.

11 erosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

12 the exception of women with active perianal Crohn's disease.

13 re strongly distinguished colonic from ileal Crohn's disease.

14 bnormal biomarkers typically associated with Crohn's disease.

15 y complex perianal fistulas in patients with Crohn's disease.

16 ut microbial Ags in a pattern reminiscent of Crohn's disease.

17 r delay postoperative clinical recurrence of Crohn's disease.

18 owel disease includes ulcerative colitis and Crohn's disease.

19 ation) in patients with treatment-refractory Crohn's disease.

20 c juvenile idiopathic arthritis, leprosy and Crohn's disease.

21 role in the pathogenesis of autoinflammatory Crohn's disease.

22 ntenance of remission in adult patients with Crohn's disease.

23 18 months after resection of all macroscopic Crohn's disease.

24 provide information about the development of Crohn's disease.

25 rovide information about the pathogenesis of Crohn's disease.

26 sen for the treatment of persons with active Crohn's disease.

27 us bacteria, running under healthy mucosa in Crohn's disease.

28 , and provide data on up to 60 patients with Crohn's disease.

29 activation of the PGD2 metabolic pathway in Crohn's disease.

30 ere related to complications and symptoms of Crohn's disease.

31 s in patients with Montreal B2 fibrostenotic Crohn's disease.

32 multiple sclerosis, rheumatoid arthritis and Crohn's disease.

33 etanercept is not effective for treatment of Crohn's disease.

34 or induction and maintenance of remission of Crohn's disease.

35 l bacteria--"dysbiosis"-is characteristic of Crohn's disease.

36 uction are noted in cells from patients with Crohn's disease.

37 of conventional management for treatment of Crohn's disease.

38 receptor A (IL-17RA) inhibition exacerbates Crohn's disease.

39 events in patients with perianal fistulizing Crohn's disease.

40 d and Drug Administration-approved drugs for Crohn's disease.

41 ssociated 4 loci with clinical phenotypes of Crohn's disease.

42 ally and biologically in the pathogenesis of Crohn's disease.

43 us adverse event was worsening of underlying Crohn's disease.

44 tween individuals with ulcerative colitis vs Crohn's disease.

45 e colitis, colonic Crohn's disease and ileal Crohn's disease.

46 intestinal CD4(+) T cells from patients with Crohn's disease.

47 g clinical remission in patients with active Crohn's disease.

48 RISK study, an inception cohort of pediatric Crohn's disease.

49 and South America, including Brazil (APC for Crohn's disease +11.1% [95% CI 4.8-17.8] and APC for ulc

50 alysis included 29,838 patients (16,902 with Crohn's disease, 12,597 with ulcerative colitis).

51 ubphenotypes to 34,819 patients (19,713 with Crohn's disease, 14,683 with ulcerative colitis) genotyp

52 00 person-years (10/100,000 person-years for Crohn's disease, 19/100,000 person-years for ulcerative

53 cerative colitis 286 per 100 000 in the USA; Crohn's disease 319 per 100 000 in Canada).

54 lcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 in Germany) and North Am

55 ]) in the tight control group, and worsening Crohn's disease (35 [29%] of 122 patients), arthralgia (

56 ture loci were mapped for 1088 patients with Crohn's disease, 361 with ulcerative colitis, 62 with IB

57 itis +14.9% [10.4-19.6]) and Taiwan (APC for Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative c

58 Nine patients out of 100 (Crohn's disease- 67, ulcerative colitis- 23 and IBDU-10)

59 e aged 18 years or older; documented to have Crohn's disease; able to speak or understand English, Fr

60 was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plus 100-point incre

61 sess Regional Homogeneity (ReHo) levels, and Crohn's Disease Activity Index (CDAI) and Inflammatory B

62 f >6 in one or more segments with ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 dependi

63 e Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with m

64 erum levels of C-reactive protein (CRP), and Crohn's disease activity index (CDAI) scores were measur

65 ree clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150).

66 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of >/=100 po

67 fecal calprotectin, C-reactive protein, and Crohn's disease activity index scores.

68 dices, such as the Mayo Clinic Score and the Crohn's Disease Activity Index; these indices incorporat

69 ystemic lupus erythematosus, celiac disease, Crohn's disease, Addison's disease, primary biliary cirr

70 he autophagy gene ATG16L1 is associated with Crohn's disease, an inflammatory bowel disease (IBD), an

71 8% and 0.3% (odds ratio 2.04; 1.59-2.62) for Crohn's disease and 1.3% and 0.7% (odds ratio 1.75; 1.44

72 Overall, 16 (72.7%) of 22 studies on Crohn's disease and 15 (83.3%) of 18 studies on ulcerati

73 o analyzed sera from 29 patients with active Crohn's disease and 33 patients with active ulcerative c

74 imens from inflamed colon of 8 patients with Crohn's disease and 8 patients with ulcerative colitis,

75 milarity between plasma palmitoleic acid and Crohn's disease and find that specific fatty acids exace

76 and Wales) who had a confirmed diagnosis of Crohn's disease and had undergone intestinal resection.

77 ons (P < 4.2 x 10(-5)) were observed between Crohn's disease and IBD and African-specific SNPs in STA

78 types, including ulcerative colitis, colonic Crohn's disease and ileal Crohn's disease.

79 immune cells among associations stronger in Crohn's disease and in gut mucosa among associations str

80 6L1 (rs2241880; T300A) increases the risk of Crohn's disease and it has been shown to enhance suscept

81 the list of susceptibility genes shared with Crohn's disease and leprosy and implicate mucosal factor

82 e placebo group had a clinical recurrence of Crohn's disease and needed anti-inflammatory rescue trea

83 opment of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis)

84 mean levels of disease activity (P = .18 for Crohn's disease and P = .14 for ulcerative colitis).

85 -derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas.

86 h defined formula diets, helps children with Crohn's disease and reduces inflammation and dysbiosis.

87 eases, including inflammatory bowel disease, Crohn's disease and rheumatoid arthritis.

88 is demonstrated through its applications to Crohn's disease and schizophrenia using the largest stud

89 es cerevisiae antibody levels is observed in Crohn's disease and this deficiency is frequently associ

90 In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex periana

91 Adult patients (>/=18 years) with Crohn's disease and treatment-refractory, draining compl

92 ope and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, comp

93 Crohn's disease and ulcerative colitis are heterogeneous

94 Crohn's disease and ulcerative colitis are the primary i

95 Crohn's disease and ulcerative colitis are the two major

96 n's disease, and ulcerative colitis) than by Crohn's disease and ulcerative colitis as currently defi

97 ng and the need for surgery in patients with Crohn's disease and ulcerative colitis have reached inco

98 c inflammatory bowel diseases (IBD) known as Crohn's disease and ulcerative colitis have shown strong

99 mmatory bowel disease, mostly shared between Crohn's disease and ulcerative colitis.

100 me to first bowel resection in patients with Crohn's disease and ulcerative colitis.

101 the pathology of inflammatory bowel disease, Crohn's disease and ulcerative colitis.

102 th a primary role for HLA-DRB1*01:03 in both Crohn's disease and ulcerative colitis.

103 (119 studies) and prevalence (69 studies) of Crohn's disease and ulcerative colitis.

104 cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with indeterminate colitis) and p

105 that are traditional for clinical trials in Crohn's disease, and identify factors that predict benef

106 isorders including Parkinson's disease (PD), Crohn's disease, and leprosy.

107 s including systemic lupus erythematosus and Crohn's disease, and relevant autoimmune mouse models.

108 ously develop chronic ileitis that resembles Crohn's disease, and that DC migration is severely impai

109 pothesis that colonic Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetica

110 three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's

111 Current smokers with Crohn's disease are at increased risk of surgery, while

112 Complex perianal fistulas in Crohn's disease are challenging to treat.

113 apies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-

114 We used Crohn's disease as an example and ranked the candidate d

115 hma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus pointing to common infl

116 ease conditions, like Alzheimer's Disease or Crohn's Disease, associated with altered autophagy.

117 but is conserved in the sequence of deafness/Crohn's disease-associated homopolymeric glycoproteins a

118 ontrast to the dogma, we find that the major Crohn's disease-associated NOD2 mutations could cause a

119 binding oligomerization domain 2 (NOD2), the Crohn's disease-associated sensor of bacterial peptidogl

120 of paediatric patients with newly diagnosed Crohn's disease at 28 sites in the USA and Canada.

121 k stratification of paediatric patients with Crohn's disease at diagnosis, and selection of anti-TNFa

122 ast 3 months, assessed as moderate-to-severe Crohn's disease at screening, defined as a Crohn's Disea

123 ssed their association with 17 phenotypes of Crohn's disease (based on disease location, disease beha

124 nd maintenance of remission in patients with Crohn's disease, based on direct and indirect evidence.

125 garding the best treatment for patients with Crohn's disease because of the lack of direct comparativ

126 non progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need

127 is an effective treatment for patients with Crohn's disease, but has never been adequately evaluated

128 composition of the intestinal microbiota in Crohn's disease, but its role on skin microbiota is unkn

129 venting postoperative clinical recurrence of Crohn's disease, but only in patients who are smokers.

130 een recommended for monitoring patients with Crohn's disease, but whether their use in treatment deci

131 ur understanding of the microbiome's role in Crohn's disease by studying a unique, well-suited cohort

132 In a cohort of patients with Crohn's disease, CCDC88B expression correlates positivel

133 nificantly greater than that between PSC and Crohn's disease (CD) (rG = 0.04) (P = 2.55 x 10(-15)).

134 ve tests for the diagnosis and assessment of Crohn's disease (CD) activity.

135 s that might decrease the risk of relapse of Crohn's disease (CD) after surgery, but it is unclear wh

136 There were 312 patients diagnosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC

137 distal ileum tissues from 6-8 patients with Crohn's disease (CD) and 6-8 individuals without CD (con

138 is strongly associated with the aetiology of Crohn's Disease (CD) and exclusive enteral nutrition (EE

139 e been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively.

140 ducted for 20 SNPs in 10 genes of paediatric Crohn's disease (CD) and for 8 SNPs in 5 genes of paedia

141 pression of PGD2 metabolic pathway actors in Crohn's disease (CD) and the ability of the enteric nerv

142 paediatric inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to

143 e-smoking interactions) that affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a ca

144 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are co

145 (IBD) consists of two main disease-subtypes, Crohn's disease (CD) and ulcerative colitis (UC); these

146 (IBD) loci, but the genetic architecture of Crohn's disease (CD) and ulcerative colitis remain incom

147 nign neoplasms, ulcerative colitis (UC), and Crohn's disease (CD) between 2005 and 2011 was obtained.

148 l diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity and are

149 l diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity and are

150 Most patients with Crohn's disease (CD) eventually require an intestinal re

151 Crohn's disease (CD) has been associated with an altered

152 Crohn's disease (CD) has the highest prevalence in Ashke

153 Genome-wide association studies in Crohn's disease (CD) have identified 140 genome-wide sig

154 Pathogenesis of Crohn's disease (CD) involves immune and microbial dysre

155 Crohn's disease (CD) is a highly heritable disease that

156 Crohn's disease (CD) is associated with a dysregulated i

157 The relationship between nutrition and Crohn's disease (CD) is complex and involves several the

158 erapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients

159 a propria (LP) macrophages may contribute to Crohn's disease (CD) pathogenesis.

160 in resting state brain activity in remissive Crohn's Disease (CD) patients after electro-acupuncture

161 Many Crohn's disease (CD) patients develop intestinal strictu

162 ced by the dramatic therapeutic responses in Crohn's disease (CD) patients induced by chimeric anti-T

163 HP prevalence in Crohn's disease (CD) patients was shown to be low compar

164 Crohn's disease (CD) usually recurs after intestinal res

165 ced by EGCs from rats and from patients with Crohn's disease (CD), compared with controls, along with

166 rative colitis (UC) and 75,971 patients with Crohn's disease (CD), from 15 countries.

167 AGI2, MAGI3, PARD3, PTEN, and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were in

168 ith a greater disease activity (p = 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (U

169 nflammatory bowel disease (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflam

170 patients with UC compared with patients with Crohn's disease (CD)-associated colitis or without infla

171 tis, which shares pathology related to human Crohn's disease (CD).

172 disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

173 he intestinal mucosa of patients with active Crohn's disease (CD).

174 Cs), has been linked consistently to risk of Crohn's disease (CD).

175 associated with a higher risk of developing Crohn's disease (CD).

176 tinal microbial dysbiosis is associated with Crohn's disease (CD).

177 ese associate with outcomes of patients with Crohn's disease (CD).

178 a cytokine implicated in the pathogenesis of Crohn's disease (CD).

179 ry tests were considered of limited value in Crohn's disease (CD).

180 ive structural bowel damage in patients with Crohn's disease (CD).

181 (sub)obstruction is a common complication of Crohn's disease (CD).

182 in phase II and III trials for patients with Crohn's disease (CD).

183 , which includes ulcerative colitis (UC) and Crohn's disease (CD).

184 13 years) newly diagnosed with IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]),

185 ts (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [contro

186 (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled in Germany fro

187 ed studies on the use of CE in patients with Crohn's disease, celiac disease, gastrointestinal bleedi

188 barrier are associated with diseases such as Crohn's disease, colitis, and colon cancer, but mechanis

189 much better explained by three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative

190 ed 913 patients, 78 (9%) of whom experienced Crohn's disease complications.

191 uggest that the inflammatory milieu found in Crohn's disease could lead to or result from deregulatio

192 primary endpoint was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plu

193 ts (aged 18-75 years) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Sev

194 ulcers in the ileum or colon, or both, and a Crohn's Disease Endoscopic Index of Severity (CDEIS) of

195 ars) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6;

196 This study supports the hypothesis that in Crohn's disease, enteric neurons and glial cells form a

197 Conventional management of Crohn's disease features incremental use of therapies.

198 s were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moder

199 genetic risk scores (GRSs) in distinguishing Crohn's disease from healthy samples, but also serve to

200 points for trials in ulcerative colitis and Crohn's disease have been based on composite indices, su

201 The risk of new-onset Crohn's disease (hazard ratio 2.19; 1.44-3.34) and ulcer

202 0.99) and a nonsignificant decreased risk of Crohn's disease (hazard ratio = 0.38, 95% confidence int

203 ease progression compared with patients with Crohn's disease (HR, 1.56; P < .001) or no IBD (HR, 1.15

204 r clinical trials of conventional therapy in Crohn's disease, HSCT resulted in clinical and endoscopi

205 k scores to test the hypothesis that colonic Crohn's disease, ileal Crohn's disease, and ulcerative c

206 n subjects with active ulcerative colitis or Crohn's disease, implicating the loss of this barrier-pr

207 we provide a physician-oriented overview of Crohn's disease in adults, ranging from epidemiology and

208 gene Atg16L1 that confers increased risk for Crohn's disease in humans.

209 l ileum <40 cm), non-stricturing, ileocaecal Crohn's disease in whom conventional therapy has failed

210 ence of inflammatory bowel diseases, such as Crohn's disease, in developed nations is associated with

211 UK, adults with non-stricturing, ileocaecal Crohn's disease, in whom conventional therapy has failed

212 Therefore, in Crohn's disease intestinal antigen taken up by lymphoid

213 erson-years (PY)) and 12 were diagnosed with Crohn's disease (IR = 9/100,000 PY).

214 n 401 colon specimens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colo

215 Crohn's disease is a chronic inflammatory condition most

216 Crohn's disease is a chronic inflammatory disease of the

217 Crohn's disease is a highly heterogeneous inflammatory b

218 ophagy in intestinal defense and suggest why Crohn's disease is associated with genetic mutations tha

219 The aetiology of Crohn's disease is complex and may include defects in pe

220 The therapeutic armamentarium for Crohn's disease is expanding, and therefore the need to

221 hat the genetic contribution to prognosis in Crohn's disease is largely independent of the contributi

222 resident intestinal E. coli associated with Crohn's disease, is characterized by enhanced epithelial

223 man disorders including Parkinson's disease, Crohn's disease, leprosy and cancer.

224 r1 displayed mucosal dysfunction and induced Crohn's disease-like ileitis following transfer into Rag

225 Crohn's disease might result from a complex interplay be

226 analyses of colon tissues from patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n =

227 vity (based on the Harvey-Bradshaw Index for Crohn's disease [n = 356] or the partial Mayo score for

228 Most patients with Crohn's disease need an intestinal resection, but a majo

229 Up to 60% of patients with Crohn's disease need intestinal resection within the fir

230 he systematic review, ulcerative colitis and Crohn's disease needed to be reported separately.

231 e patients were aged 18-80 years, had active Crohn's disease of the terminal ileum, and had not respo

232 with high rates of relapse in patients with Crohn's disease or ulcerative colitis (approximately 75%

233 ies reporting the incidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later

234 ge psychological conditions in patients with Crohn's disease or ulcerative colitis is necessary for t

235 n with inflammatory bowel disease (IBD; i.e. Crohn's disease or ulcerative colitis) and typically dev

236 in patients with gastrointestinal bleeding, Crohn's disease, or celiac disease, who have had negativ

237 (S727) response in patients with Montreal B2 Crohn's disease, particularly in response to IL-6 leadin

238 genes that are likely to be associated with Crohn's disease pathogenesis, and our rank of candidate

239 ytometry in blood and intestinal tissue from Crohn's disease patients (CD patients) and healthy contr

240 and clinical Crohn's disease phenotype in 69 Crohn's disease patients and 30 age- and sex-matched hea

241 ApoA1 expression, which is downregulated in Crohn's disease patients and causally linked to colitis

242 ccording to the Montreal classification: 4/6 Crohn's disease patients are B1, 2/6 Crohn's disease pat

243 on: 4/6 Crohn's disease patients are B1, 2/6 Crohn's disease patients are B2, 2/2 ulcerative colitis

244 sis finds that gut microbiota collected from Crohn's disease patients are functionally distinct from

245 ebsiella strains isolated from the saliva of Crohn's disease patients can induce Th1 cell responses t

246 Further, a subset of ileal Crohn's disease patients displayed MDR1 loss of function

247 These results provide evidence that Crohn's disease patients have an impairment in MBL-MASP

248 hisms in a well-characterized cohort of 1090 Crohn's disease patients of European ancestry.

249 up of isolates from the intestinal mucosa of Crohn's disease patients that can invade intestinal epit

250 fully improved anemia in clinical responsive Crohn's disease patients, and DMT1 was found to be marke

251 ma(+)ILC2 ex vivo in intestinal samples from Crohn's disease patients.

252 e protease (MBL-MASP) functional activity in Crohn's disease patients.

253 In patients with Crohn's disease, perianal fistulas recur frequently, cau

254 i-S. cerevisiae antibody levels and clinical Crohn's disease phenotype in 69 Crohn's disease patients

255 iency is frequently associated with a severe Crohn's disease phenotype.

256 al of 57 markers with strong associations to Crohn's disease phenotypes (P < 2 x 10(-4)) were subsequ

257 ted the association of 4 loci with different Crohn's disease phenotypes.

258 A 34 year-old Caucasian woman with Crohn's disease presented to the emergency department wi

259 genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangit

260 herapy alone for prevention of postoperative Crohn's disease recurrence.

261 Crohn's disease-related inflammation is characterized by

262 bined with biomarkers in patients with early Crohn's disease results in better clinical and endoscopi

263 th inflammatory autoimmune disorders such as Crohn's disease, rheumatoid arthritis, and ankylosing sp

264 ve variably beneficial effects in psoriasis, Crohn's disease, rheumatoid arthritis, psoriatic arthrit

265 ry rare, damaging missense variants in known Crohn's disease risk genes, suggesting that more compreh

266 tive to LACC1 Ile254, cells transfected with Crohn's disease-risk LACC1 Val254 or LACC1 with mutation

267 APCs in intestinal tissue from patients with Crohn's disease show selective failure in PD-L1 expressi

268 Ileal Crohn's disease subjects deviated most from the HP, espe

269 nth infection protects mice deficient in the Crohn's disease susceptibility gene Nod2 from intestinal

270 be critical for signaling downstream of the Crohn's disease susceptibility protein nucleotide-bindin

271 than conventional management for controlling Crohn's disease symptoms, the risk of major adverse outc

272 tissues from patients with UC, but not ileal Crohn's disease, than control tissues; levels of GATA3 c

273 patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab

274 iduals with select nonpsychiatric disorders (Crohn's disease, type 1 and type 2 diabetes mellitus, mu

275 SDMB SNPs and an increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

276 crobiota are involved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

277 atients were 17 years old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified

278 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bow

279 Granulomatous inflammation consistent with Crohn's disease was found on histopathological examinati

280 if it was imperative to know whether active Crohn's disease was present in the small bowel.

281 , which is associated with susceptibility to Crohn's disease, was significantly correlated with an im

282 "The Treatment-Naive Microbiome in New-Onset Crohn's Disease," was designed to improve our understand

283 matory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the whole genomes of 4,280

284 ent of certain inflammatory diseases such as Crohn's disease, Wegener's granulomatosis, or sarcoidosi

285 3 or 4 neutropenia, candida infections, and Crohn's disease were 0.7, 0.9, and 0.7 cases per 100 pat

286 Current smokers with Crohn's disease were at increased risk of intestinal res

287 atients with refractory perianal fistulizing Crohn's disease were randomly assigned to groups given i

288 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to mercaptop

289 groups (198 blood donors, 151 patients with Crohn's disease) were analyzed using the assay, as well

290 t into mechanisms underlying exacerbation of Crohn's disease when IL-17A or IL-17RA is inhibited.

291 patients with suspected, known, or relapsed Crohn's disease when ileocolonoscopy and imaging studies

292 s, IL-12 and IL-23 p40 inhibition attenuates Crohn's disease, whereas IL-17A or IL-17 receptor A (IL-

293 r complex perianal fistulas in patients with Crohn's disease who did not respond to conventional or b

294 Most studies of patients with Crohn's disease who discontinued an immunomodulator afte

295 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necr

296 Treatment of patients with ileocaecal Crohn's disease who have not responded to conventional t

297 ected from patients with treatment-resistant Crohn's disease who participated in a trial of ustekinum

298 We found that study participants with Crohn's disease who received mongersen had significantly

299 outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control al

300 oing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anast